ZMI Management Inc. Acquires ZIMHI™ from DMK Pharmaceuticals; Partners with FFF Enterprises as Exclusive Distributor

ZMI Pharma, Inc., based in San Diego, recently announced the completion of acquiring essential assets to manufacture ZIMHI™, a life-saving medication designed for opioid overdose emergencies. This acquisition includes patents, inventory, automated assembly systems, and the retention of two key members from the previous management team. The purchase was finalized through a section 363 sale in Federal Bankruptcy court. Additionally, ZMI Pharma has formed an exclusive distribution agreement with FFF Enterprises for ZIMHI™.

ZIMHI™ is an opioid antagonist used in emergency situations to treat known or suspected opioid overdoses, including fentanyl poisoning. It addresses respiratory and central nervous system depression in both adults and children. ZIMHI™ delivers the highest available dose of naloxone through a 5 mg/0.5 mL intramuscular injection, packaged in a pre-filled, single-dose syringe, and available by prescription.

Currently, ZIMHI™ is being sold by FFF Enterprises at a public interest price of $44.00 for a two-dose carton. To ensure a continuous supply, ZMI Pharma plans to begin manufacturing ZIMHI™ at their new facility in Carlsbad, California, starting October 2024.

John Jellinek, CEO of ZMI Pharma, expressed enthusiasm about the acquisition, emphasizing the importance of ZIMHI™ in tackling the opioid crisis. He highlighted the medication's high naloxone concentration and efficient delivery system as vital tools in addressing the increasing cases of fentanyl overdoses. Jellinek also underscored the strategic partnership with FFF Enterprises, which will enable competitive pricing and timely distribution, ultimately saving lives.

Patrick M. Schmidt, CEO of FFF Enterprises, shared similar sentiments, noting the honor of being the exclusive distributor of ZIMHI™. Schmidt pointed out that this partnership allows FFF Enterprises to offer a complete range of naloxone products, including various nasal spray formulations. This collaboration reinforces FFF Enterprises' position as a comprehensive resource for communities seeking effective overdose solutions.

ZMI Pharma, Inc. is a newly established California corporation founded by Richard Hertzberg, John Jellinek, and Sam Kabbani. The founders bring extensive experience in life sciences, addiction management, and research and development program management. ZMI Pharma aims to start producing ZIMHI™ in Carlsbad, California, from October 2024, while the current stock is available through FFF Enterprises to meet ongoing demands.

FFF Enterprises, a leading supplier of critical-care biopharmaceuticals, plasma products, and vaccines since 1988, is known for its commitment to safety and customer-driven innovation. The company boasts a robust national salesforce, local representatives, and support services such as on-call infusion, specialty pharmacy, and reimbursement advisors. With partnerships including major Group Purchasing Organizations (GPOs) and annual sales exceeding five billion dollars, FFF Enterprises has established itself as a trusted distributor of human blood products, vaccines, and critical biopharmaceuticals in the United States.